

CITATION REPORT

List of articles citing

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

DOI: 10.1016/s1470-2045(14)70319-5
Lancet Oncology, The, 2014, 15, 966-74.

Source: <https://exaly.com/paper-pdf/59347592/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
312	Section on Child Neurology: Morning Meeting, 9:00 A.M., Friday, April 30, 1965. 1965 , 15, 292-292		0
311	Anti-IL6-Antikörper punktet bei M. Castleman. 2014 , 17, 22-22		
310	Exploiting interleukin 6 in multicentric Castleman's disease. <i>Lancet Oncology, The</i> , 2014 , 15, 910-2	21.7	9
309	Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. 2014 , 124, 3544-52		67
308	Understanding anemia of chronic disease. 2015 , 2015, 14-8		38
307	Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. 2015 , 3, 472-8		31
306	Malignant causes of fever of unknown origin. 2015 , 15, 292-4		23
305	Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6. 2015 , 80, 687-97		9
304	Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. 2015 , 169, 834-42		43
303	Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. 2015 , 67, 930-2		8
302	Siltuximab (CNTO 328): a promising option for human malignancies. 2015 , 9, 3455-8		39
301	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. 2015 , 6, 30408-19		37
300	Clinical development of siltuximab. 2015 , 17, 29		6
299	US FDA oncology drug approvals in 2014. 2015 , 11, 1931-45		5
298	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. 2015 , 4, e985940		38
297	CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. 2015 , 8, 343-54		22
296	FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. 2015 , 21, 950-4		70

295	Novel investigational drugs targeting IL-6 signaling for the treatment of depression. 2015 , 24, 459-75	35
294	Interleukin-6 as a therapeutic target. 2015 , 21, 1248-57	218
293	Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. 2015 , 67, 280-309	224
292	Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. 2015 , 8, 207-16	15
291	Multicentric Castleman's disease with voltage-gated potassium channel antibody-positive limbic encephalitis: a case report. 2015 , 15, 4	2
290	Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. 2015 , 9, 45	4
289	Everything old is neu again: cellular senescence in HER2-positive breast cancer. 2015 , 107,	2
288	Dose selection of siltuximab for multicentric Castleman's disease. 2015 , 75, 1037-45	10
287	Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease. 2015 , 94, 1241-3	4
286	Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease. 2015 , 29, 399-406	2
285	Siltuximab for Multicentric Castleman Disease-Letter. 2015 , 21, 4740	1
284	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. 2015 , 21, 4294-304	59
283	Achieving incompatible transplantation through desensitization: current perspectives and future directions. 2015 , 7, 377-98	19
282	Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV8). 2016 , 549-574	
281	Update and new approaches in the treatment of Castleman disease. 2016 , 7, 145-58	59
280	Emerging treatments in Castleman disease - a critical appraisal of siltuximab. 2016 , 10, 9-15	3
279	Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor- β -positive breast cancer. 2016 , 8, 13-27	13
278	Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1 β regulation. 2016 , 12, 4665-4670	12

277	Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. 2016 , 95, e5047	3
276	Lymphoid Interstitial Pneumonia and Other Benign Lymphoid Disorders. 2016 , 37, 406-20	14
275	Practical Management of Castleman's Disease. 2016 , 136, 16-22	1
274	Multicentric Castleman disease: Where are we now?. 2016 , 33, 294-306	61
273	STAT3 Inhibitors in Cancer: A Comprehensive Update. 2016 , 95-161	9
272	STAT Inhibitors in Cancer. 2016 ,	
271	Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes. 2016 , 37, 603-30	15
270	Revisiting IL-6 antagonism in multiple myeloma. 2016 , 105, 1-4	37
269	Castleman Disease of the Thorax: Clinical, Radiologic, and Pathologic Correlation: From the Radiologic Pathology Archives. 2016 , 36, 1309-32	28
268	Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. 2016 , 14, 89	42
267	Review of siltuximab in the treatment of multicentric Castleman's disease. 2016 , 7, 360-366	29
266	Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan--two case studies. 2016 , 96, 541-3	4
265	Hyaline-Vascular Type Castleman's Disease, Sarcoidosis, and Crohns Disease. 2016 , 32, 335-9	4
264	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. 2016 , 8, 17-26	18
263	Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. 2016 , 21, 180-189	46
262	Idiopathic multicentric Castleman's disease: a systematic literature review. 2016 , 3, e163-75	152
261	The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. 2016 , 3, e150-2	30
260	Current diagnosis and treatment of Castleman's disease. 2016 , 216, 146-156	

259	STAT3 in the systemic inflammation of cancer cachexia. 2016 , 54, 28-41	119
258	HIV-associated Hematological Malignancies. 2016 ,	4
257	HIV-Associated Multicentric Castleman Disease. 2016 , 197-205	
256	Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease. 2016 , 32, 1193-200	3
255	Current diagnosis and treatment of Castleman's disease. 2016 , 216, 146-56	7
254	Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. 2016 , 28, 181-8	75
253	Loss of interleukin-21 leads to atrophic germinal centers in multicentric Castleman's disease. 2016 , 95, 35-40	9
252	International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. 2017 , 129, 1646-1657	234
251	Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. 2017 , 26, 367-373	6
250	Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8-Negative Castleman Disease. 2017 , 153, 381-382	
249	Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. 2017 , 129, 1658-1668	88
248	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. 2017 , 13, 535-551	114
247	Case 5-2017. A 19-Year-Old Man with Hematuria and a Retroperitoneal Mass. 2017 , 376, 684-692	8
246	Monoclonal Serotherapy. 2017 , 1-23	3
245	Neoplasms in Acquired Immunodeficiency Syndrome. 2017 , 1-23	
244	[Castleman's Disease - A Case Series of a Rare Lymphoproliferative Disease]. 2017 , 96, 522-527	2
243	Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. 2017 , 101, 32-44	144
242	Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis. 2017 , 8, 15433	83

241	Cancer clinical trials in persons with HIV infection. 2017 , 12, 84-88	11
240	Unraveling Castleman: progress in a complex process. 2017 , 129, 1570	1
239	Multicentric Castleman disease: consensus at last?. 2017 , 129, 1569-1570	1
238	Rare B Cell Lymphoproliferative Disorders. 2017 , 760-775	
237	Anemia of Inflammation: A Review. 2017 , 101, 285-296	90
236	Implications of weight loss for cancer patients receiving radiotherapy. 2017 , 11, 261-265	8
235	Senescent cells: an emerging target for diseases of ageing. 2017 , 16, 718-735	488
234	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. 2017 , 189, 31-39	1
233	Therapeutic outlook for Castleman's disease: prospects for the next decade. 2017 , 5, 633-640	1
232	The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease. 2017 , 66, 156-164	46
231	Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. 2017 , 12, 176-189	28
230	Biology and Management of Unusual Plasma Cell Dyscrasias. 2017 ,	
229	POEMS Syndrome and Castleman's Disease. 2017 , 41-69	2
228	Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. 2017 , 76, 779-788	39
227	Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma. 2017 , 26, 1584-1596	24
226	TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature. 2017 , 4, 149	20
225	Hodgkin Lymphoma and Castleman Disease: When One Blood Disease Can Hide Another. 2017 , 2017, 9423205	7
224	Rituximab Monotherapy in the Management of a Rare Case of an HIV Associated Lymphoproliferative Disorder. 2017 , 2017, 5235163	

223	Leveraging information and collaboration to cure disease. 2017 , 37, 307-311	
222	Introduction to Cytokines as Tissue Regulators in Health and Disease. 2017 , 3-30	1
221	Canakinumab and Lung Cancer: Intriguing, but Is It Real?. 2018 , 23, 637-638	13
220	Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. 2018 , 93, 902-912	33
219	Targeting the IL-6/JAK/STAT3 signalling axis in cancer. 2018 , 15, 234-248	975
218	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). 2018 , 24 Suppl 2, S21-S40	114
217	Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. 2018 , 32, 75-88	22
216	Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. 2018 , 109, 199-206	30
215	The unholy trinity of human herpesvirus 8-associated malignancy in a person living with HIV-1. 2018 , 32, 404-406	1
214	Interleukin-6: designing specific therapeutics for a complex cytokine. 2018 , 17, 395-412	272
213	Successful treatment of disseminated Rosai-Dorfman disease with siltuximab. 2018 , 103, e325-e328	1
212	Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators?. 2018 , 128, 88-100	22
211	Treatment of Idiopathic Castleman Disease. 2018 , 32, 89-106	29
210	The Role of Interleukin-6 in Castleman Disease. 2018 , 32, 23-36	22
209	Clinical, laboratory and imaging findings in Castleman's disease - The subtype decides. 2018 , 32, 225-234	15
208	Castleman Disease Pathogenesis. 2018 , 32, 11-21	43
207	Pathology of Castleman Disease. 2018 , 32, 37-52	45
206	TAFRO Syndrome. 2018 , 32, 107-118	24

205	The full spectrum of Castleman disease: 273 patients studied over 20 years. 2018 , 180, 206-216	71
204	Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report. 2018 , 57, 703-705	3
203	Strategies targeting cellular senescence. 2018 , 128, 1247-1254	102
202	Variant of plasmablastic microlymphoma in Castleman disease: a case report and review of the literature. 2018 , 12, 276-279	
201	The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. 2018 , 46, 1449-1462	51
200	Do you know TAFRO?. 2018 , 132, 2109-2110	1
199	Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. 2018 , 132, 2323-2330	47
198	Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?. 2018 , 32, 531-546	31
197	IL-6: a cytokine at the crossroads of autoimmunity. 2018 , 55, 9-14	43
196	Cytokine release syndrome. 2018 , 4, 134-141	9
195	Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial. 2018 , 19, 168	19
194	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. 2018 , 132, 2115-2124	127
193	Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease. 2018 , 9, 35-41	13
192	Pediatric Cervical Lymphadenopathy. 2018 , 39, 433-443	25
191	Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. 2018 , 2018, 318-325	5
190	Unicentric Castleman disease in the mediastinum. 2018 , 34, 51-53	
189	Emerging Molecular Targets for Anti-Cancer Drug Design. 2018 , 12, 88-99	
188	Virus-Associated Lymphoma. 2018 , 1318-1329.e3	

187	Ontology and Function of Fibroblast-Like and Macrophage-Like Synoviocytes: How Do They Talk to Each Other and Can They Be Targeted for Rheumatoid Arthritis Therapy?. 2018 , 9, 1467	37
186	Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. 2018 , 97, 1641-1647	7
185	Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately. 2018 , 144, 1265-1277	2
184	TAFRO syndrome: current perspectives. 2018 , 9, 15-23	15
183	ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. 2018 , 142,	18
182	Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. 2018 , 36, 689-692	4
181	Tafro syndrome: Critical review for clinicians and pathologists. 2018 , 128, 88-95	9
180	Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016. 2019 , 111, 449-458	12
179	Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review. 2019 , 26, 197-202	4
178	Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital. 2019 , 60, 3442-3448	4
177	Modulation of Angiogenic Processes by the Human Gammaherpesviruses, Epstein-Barr Virus and Kaposi's Sarcoma-Associated Herpesvirus. 2019 , 10, 1544	9
176	Osteosarcoma Manifesting Systemic Inflammation and Histological Features Mimicking Plasma Cell-type Castleman Disease. 2019 , 58, 2555-2560	3
175	Storming the Castle with TCP. 2019 , 133, 1697-1698	1
174	Targeting Interleukin-6 Signaling in Clinic. 2019 , 50, 1007-1023	323
173	Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. 2019 , 50, 812-831	182
172	Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. 2019 , 133, 1720-1728	21
171	Targeting senescent cells in translational medicine. 2019 , 11, e10234	92
170	CD20-negative primary middle ear diffuse large B-cell lymphoma coexpressing MYC and BCL-2 secondary to acute lymphoblastic leukemia: A case report. 2019 , 98, e15204	1

169	Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. 2019 , 184, 232-241	21
168	Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis. 2019 , 177, 23-62	9
167	Peripheral nervous system involvement in lymphomas. 2019 , 24, 5-18	24
166	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. 2019 , 33, 45-60	46
165	Rare Rheumatic Diseases of Immunologic Dysregulation. 2019 ,	
164	Castleman's Disease. 2019 , 121-138	
163	AIDS-Associated Malignancies. 2019 , 177, 1-21	21
162	A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. 2019 , 29, 302-305	8
161	Association of vascular endothelial growth factor and renal thrombotic microangiopathy-like lesions in patients with Castleman's disease. 2020 , 25, 125-134	5
160	Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. 2020 , 143, 73-77	1
159	Periodic and Non-Periodic Fevers. 2020 ,	
158	Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease. 2020 , 188, e64-e67	4
157	Management of Cytokine Release Syndrome. 2020 , 45-64	1
156	Cytokine-Targeted Therapeutics for KSHV-Associated Disease. 2020 , 12,	6
155	A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. 2020 , 25, 963-973	4
154	The genetics of asthma and the promise of genomics-guided drug target discovery. 2020 , 8, 1045-1056	33
153	From pathogenesis to personalized treatments of neuropathies in hematological malignancies. 2020 , 25, 212-221	4
152	Hepatocellular Senescence: Immunosurveillance and Future Senescence-Induced Therapy in Hepatocellular Carcinoma. 2020 , 10, 589908	5

151	FDG PET/CT Findings of Castleman Disease Assessed by Histologic Subtypes and Compared with Laboratory Findings. 2020 , 10,	3
150	Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature. 2020 , 21, 528	1
149	Interleukin-6 in Rheumatoid Arthritis. 2020 , 21,	32
148	A Case of Rapid Deterioration with Marked Hypergammaglobulinemia. 2020 , 66, 1373-1378	
147	Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. 2020 , 56,	98
146	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. 2020 , 95, 1553-1561	9
145	Pharmacological treatments of COVID-19. 2020 , 72, 1446-1478	16
144	Application of Anti-Inflammatory Agents in Prostate Cancer. 2020 , 9,	7
143	Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways. 2020 , 17, 192	11
142	Increased mTOR activation in idiopathic multicentric Castleman disease. 2020 , 135, 1673-1684	24
141	mTOR signaling as a driver of Castleman disease. 2020 , 135, 1614-1615	0
140	A pediatric case of tocilizumab-resistant TAFRO syndrome treated successfully with rituximab. 2020 , 67, e28489	2
139	HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis. 2020 , 13,	1
138	Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19. 2020 , 27, 297-298	29
137	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. 2020 , 34, 415-422	39
136	Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition. 2020 , 34, 211-234	10
135	Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease. 2020 , 413, 116771	3
134	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. 2020 , 20, 653-664	18

133	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. 2020 , 7, e209-e217	17
132	COVID-19 and autism. 2020 , 142, 109797	10
131	Translating IL-6 biology into effective treatments. 2020 , 16, 335-345	164
130	Overview of Castleman disease. 2020 , 135, 1353-1364	71
129	The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. 2020 , 15, 95	6
128	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. 2021 , 45, 100707	92
127	Response assessment and salvage indication for idiopathic multicentric Castleman disease. 2021 , 62, 1016-1017	
126	Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. 2021 , 26, 4-6	1
125	Cellular senescence in ageing: from mechanisms to therapeutic opportunities. 2021 , 22, 75-95	191
124	Hemoglobin and C-reactive protein levels as predictive factors for long-term successful glucocorticoid treatment for multicentric Castleman's disease. 2021 , 62, 614-619	2
123	Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. 2021 , 192, e28-e31	2
122	Castleman Disease with Mesenteric Involvement. 2021 , 321-325	
121	Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration. 2021 , 18, 32	20
120	Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection. 2021 , 11, 580679	3
119	Recurrent episodes of renal impairment with cytopenias and lymphadenopathy. 2021 , 82, 1-5	
118	Cutaneous involvement as initial presentation of multicentric plasmacytic Castleman disease. 2021 , 48, 701-705	0
117	The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease. 2021 , 36, 424-432	3
116	Morbus Castleman Ein seltenes, heterogenes Krankheitsbild. 2021 , 16, 198-206	

115	Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports. 2021 , 15, 105	1
114	Rare Diseases of the Orbit. 2021 , 100, S1-S79	2
113	Donor-derived human herpesvirus 8 infection with Kaposi sarcoma and Kaposi sarcoma inflammatory cytokine syndrome in a heart transplant recipient: A case report. 2021 , 23, e13609	1
112	Patient's age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. 2021 , 114, 179-188	2
111	TAFRO syndrome mimicking systemic lupus erythematosus: Case report and literature review. 2021 , ,	1
110	The role of IL-6 and IL-6 blockade in COVID-19. 2021 , 17, 601-618	10
109	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. 2021 , 35, 2710-2714	13
108	Recent advances in antibody-based immunotherapy strategies for COVID-19. 2021 , 122, 1389-1412	9
107	Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. 2021 , 11, 51	1
106	Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation. 2021 , 62, 3031-3034	1
105	Hypersensitivity and Immune-related Adverse Events in Biologic Therapy. 2021 , 1	2
104	Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. 2021 , 68, e29261	0
103	Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. 2021 , 5, 3445-3456	2
102	The management of Castleman disease. 2021 , 195, 328-337	0
101	Retrohepatic Mass: A Case of Human Herpesvirus-8 Negative Multicentric Castleman's Disease. 2021 , 13, e16848	
100	Efficacy and safety of rituximab in autoimmune pancreatitis type 1: our experiences and systematic review of the literature. 2021 , 56, 1355-1362	0
99	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. 2021 , 107, 642-649	1
98	TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy. 2021 , 14, 1359-1365	0

97	The promise and perils of immunotherapy. 2021 , 5, 3709-3725	4
96	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. 2021 , 12, 752227	5
95	IL-6/STAT3 signaling activation exacerbates high fructose-induced podocyte hypertrophy by ketohexokinase-A-mediated tristetraprolin down-regulation. 2021 , 86, 110082	1
94	Triology of human herpesvirus type-8: A rare and fatal case report of primary effusion lymphoma, Kaposi sarcoma and Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS). 2021 , 4, 100084	1
93	Updates on the diagnosis and management of multicentric Castleman disease. 2021 , 33, 22-28	2
92	Adipose Tumor Microenvironment. 2020 , 1226, 73-86	5
91	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. 2020 , 1, 100158	5
90	The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases. 2019 , 3, 97-105	3
89	Discovering in vivo cytokine eQTL interactions from a lupus clinical trial.	3
88	The potential role of IL-6 in monitoring severe case of coronavirus disease 2019.	64
87	Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. 2020 , 5,	13
86	Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. 2019 , 129, 4451-4463	48
85	Targeting the mTOR pathway in idiopathic multicentric Castleman disease. 2019 , 129, 4086-4088	3
84	Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. 2016 , 126, 3165-75	123
83	Early IL-6 signalling promotes IL-27 dependent maturation of regulatory T cells in the lungs and resolution of viral immunopathology. 2017 , 13, e1006640	70
82	The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. 2020 , 12, e12421	163
81	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. 2016 , 7, 67956-67965	4
80	Adamantinomatous craniopharyngioma: moving toward targeted therapies. 2020 , 48, E7	12

79	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. 2016 , 22, 7440-52	13
78	Biologic Agents in the Treatment of Multicentric Castleman Disease. 2018 , 19, 220-225	3
77	Transcriptome and unique cytokine microenvironment of Castleman disease. 2021 ,	0
76	Drugs and liver injury: a not to be overlooked binomial in COVID-19. 2021 , 1-14	1
75	Neue Arzneimittel 2014. 2015 , 37-198	3
74	Intrathoracic Castleman's disease: "An important clinical mimicker". 2017 , 34, 197-199	2
73	Idiopathic Multicentric Castleman's Disease with Normal Interleukin-6 Levels. 2018 , 6,	
72	Evaluation of Zataria multiflora Boiss. (Shirazi Thyme) Hydro Alcoholic Extract Effect on Pro-Inflammatory Cytokine IL-6 Different Transcript Variants Expression Level in Mesenchymal Stem Cells (MSCs). 2018 , In Press,	
71	CD20-Negative Aggressive Lymphomas. 2019 , 213-226	
70	Castleman Disease. 2020 , 215-228	
69	Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research. 2015 , 88, 383-8	4
68	[Progress in the diagnosis and treatment of Castleman disease]. 2020 , 41, 697-700	0
67	[Analysis of the clinical characteristics and prognosis of 20 patients with multicenter Castleman disease]. 2021 , 42, 510-513	
66	[The consensus of the diagnosis and treatment of Castleman disease in China (2021)]. 2021 , 42, 529-534	
65	Multicentric Castleman disease and the evolution of the concept. 2021 , 113, 339-353	1
64	Castleman disease. 2021 , 7, 84	3
63	Senescence in chronic wounds and potential targeted therapies.. 2022 , 10, tkab045	1
62	Harnessing cytokines and chemokines for cancer therapy.. 2022 ,	15

61	Multizentrischer Morbus Castleman: Selten korrekt diagnostiziert.	
60	Siltuximab treatment of Castleman's Disease could interfere with the diagnostic process of cellulitis. 2021 ,	
59	Profound thrombocytopenia associated with administration of multiple anti-inflammatory agents in baboons.. 2022 ,	1
58	A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab.. 2022 , 39, 1126	2
57	A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.. 2022 , 1-9	0
56	Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.. 2022 , 30, 23	0
55	A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential.. 2021 , 12, 816646	2
54	To and TAFRO - a cryptic cause of acute renal failure: a case report.. 2022 , 23, 19	
53	Multicentric Castleman disease - a single center experience of treatment with a focus on autologous stem cell transplantation.. 2022 ,	0
52	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.. 2022 , 8, 16	1
51	Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6R α to inhibit IL-6/IL-6R α /gp130 hexameric signaling complex formation.. 2022 , 14, 2029675	1
50	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. 2022 , 58,	0
49	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. 2022 , 20, 1721727X2210787	
48	Multicentric Castleman's disease. Symptoms, diagnostics and therapy. 2022 , 68, 41-53	
47	Drug Discovery in Spinal Cord Injury With Ankylosing Spondylitis Identified by Text Mining and Biomedical Databases.. 2022 , 13, 799970	0
46	From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance.. 2022 , 14,	1
45	Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis.. 2022 , 298, 120516	0
44	Glycogen synthase kinase 3 β /CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO. 2021 ,	

- 43 Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs.. **2022**, 23, 1
- 42 Quintessential Case of POEMS Syndrome Associated With Multicentric Castleman Disease. 263394472210863
- 41 A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES.. **2021**, 10, 14-22
- 40 The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.. **2022**, 0
- 39 Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.. **2022**, 18, 499-509 0
- 38 Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.. **2022**,
- 37 Nearly 70 years later: the continued unraveling of Castleman Disease.. **2022**,
- 36 The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.. **2022**,
- 35 Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease. **2022**, 13,
- 34 Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass. **2022**, 386, 2036-2048 0
- 33 Current status and prospects of IL-6 targeting therapy. 1-18 1
- 32 Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
- 31 Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. 13,
- 30 Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review. 0
- 29 Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. annrheumdis-2022-222784 1
- 28 Inflammatory diseases in hematology: a review.
- 27 Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. **2022**, 387, 762-764
- 26 Long-term treatment outcome of Castleman disease: A real-world experience. 12,

25	Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study. 1-10	1
24	A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. 2022 , 8, e002359	1
23	The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.	0
22	Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine. 2022 , 10, 1725	1
21	IL-6-targeted therapies directed to cytokine or receptor blockade drive distinct alterations in T cell function.	0
20	Monoclonal Antibody and Targeted Toxin Therapy. 1-31	0
19	Oncogenic viruses, cancer biology, and innate immunity. 2022 , 78, 102253	0
18	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12	0
17	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. 2022 , 12, 1758	2
16	Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy.	0
15	Interleukin-6 Targeted Agents. 2022 , 187-197	0
14	Immune-Targeted Therapies for COVID-19. 2022 , 451-468	0
13	CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease. 2022 , 13,	0
12	Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report. 2022 , 101, e32200	0
11	Case report: Importance of early and continuous tocilizumab therapy in nephrotic syndrome associated with idiopathic multicentric Castleman disease: A case series. 9,	0
10	Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. 2023 , 9,	1
9	Approche thérapeutique des maladies de Castleman : l'émergence des thérapies ciblées. 2022 , 43, 10S26-10S33	0
8	Blocage de l'IL-6 hors autorisation de mise sur le marché 2022 , 215-224	0

- 7 Castleman Disease. **2023**, 727-735
- 6 TAFRO syndrome mimicking systemic lupus erythematosus: Case report and literature review. **2022**, 29, 373-383
- 5 Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies. **2023**, 12, 915
- 4 A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. **2023**, 100720
- 3 Paraneoplastic pemphigus and Castleman disease: a case report and a revision of the literature. **2023**, 49,
- 2 Biologic Response Modifiers. **2023**, 1089-1101
- 1 Anemia of chronic diseases: a verdict or a protective reaction of the body?.